Skip to content

The median effective dose(ED50) of remimazolam combined with nalbuphine in hysteroscopy under monitoring anesthesia.

The median effective dose(ED50) of remimazolam combined with nalbuphine in hysteroscopy under monitoring anesthesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078712
Enrollment
Unknown
Registered
2023-12-15
Start date
2023-12-15
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diseases of uterine cavity

Interventions

Experimental group:According to the improved Dixon sequential method, the first patient s dose of remimazolam was set at 0.2 mg/kg. If the patient has a MOAA/S score of = 4 or experiences reactions s

Sponsors

The first affiliated hospital of henan university of CM
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Can understand and sign informed consent forms; (2) Age = 18 years and = 60 years old; (3) ASA is classified as Grade I or II; (4) BMI 18-30 kg/m2 (5) There is no allergy or intolerance to the research medication; (6) Meets the indications for hysteroscopy surgery; (7) Not involved in other clinical studies.

Exclusion criteria

Exclusion criteria: Patients with allergic reaction to narcotics, contraindication to hysteroscopy surgery;heart, liver and kidney dysfunction, history of asthma, alcohol abuse, mental illness, and diabetes mellitus; Patients who have taken Benzodiazepines or opioid drugs intermittently within the past 3 months or continuously within 1 month.

Design outcomes

Primary

MeasureTime frame
BIS;

Secondary

MeasureTime frame
Adverse reactions such as intravenous injection pain, nausea and vomiting, muscle stiffness, respiratory depression, etc;Patient and surgeon satisfaction;

Countries

China

Contacts

Public Contactzhang yi

The first affiliated hospital of henan university of CM

290364006@qq.com+86 155 1753 3365

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026